Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)

In a report released on December 18, Laura Chico from Wedbush maintained a Buy rating on BioCryst, with a price target of $21.00. The company’s shares closed last Friday at $7.29.

Claim 70% Off TipRanks This Holiday Season

• Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Chico is a 5-star analyst with an average return of 11.4% and a 51.22% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, BioCryst, and Denali Therapeutics.

BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $19.45, implying a 166.80% upside from current levels. In a report released on December 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $32.00 price target.

Based on BioCryst’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $159.4 million and a net profit of $12.9 million. In comparison, last year the company earned a revenue of $117.09 million and had a GAAP net loss of $14.03 million

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year. Earlier this month, Alane Barnes, the CLO of BCRX sold 50,906.00 shares for a total of $367,032.26.